Pharmacology
Tumor necrosis factor promotes the inflammatory response, which, in turn, causes many of the clinical problems associated with autoimmune disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma. These disorders are sometimes treated by using a TNF inhibitor. This inhibition can be achieved with a monoclonal antibody such as infliximab (Remicade), adalimumab (Humira) or certolizumab pegol (Cimzia), or with a circulating receptor fusion protein such as etanercept (Enbrel).
Read more about this topic: Tumor Necrosis Factor-alpha